Healthcare Industry News: galeterone
News Release - June 12, 2012
Tokai Pharmaceuticals’ Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate CancerCAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate, galeterone (TOK-001), has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of metastatic castration-resistant prostate cancer (CRPC). Tokai recently completed ARMOR1, a Phase 1 proof-of-concept study of galeterone in patients with CRPC, part of the ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program, and Tokai plans to initiate a Phase 2 clinical trial in patients with CRPC in the second half of the year.
“We are very pleased with this Fast Track designation and believe the FDA’s decision further validates the potential therapeutic utility of galeterone for the treatment of prostate cancer,” said Martin D. Williams, president and chief executive officer, Tokai Pharmaceuticals. “Despite recent progress in prostate cancer treatment, CRPC often becomes resistant to androgen deprivation therapy and galeterone’s unique triple mechanism of action may offer an important therapeutic advance. We are very encouraged by the recent positive results from our ARMOR1 clinical study, and we look forward to advancing galeterone into Phase 2 development in patients with CRPC later this year.”
Under the FDA Modernization Act of 1997, the Fast Track process was designed to facilitate the development and expedite the review of drug candidates intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. A drug that receives Fast Track designation is eligible for Accelerated Approval, which provides for a potential approval by the FDA on the basis of a demonstrated effect on a surrogate endpoint deemed reasonably likely to predict clinical benefit, and Rolling Review, which facilitates the submission of individual sections of a New Drug Application (NDA) as they are completed for review by FDA. Most drugs that are eligible for Fast Track designation are also considered appropriate to receive Priority Review, designed to reduce the time required for FDA review. In addition, Fast Track designation for a potential drug may allow more frequent meetings between the sponsor and FDA to discuss the proposed development plan and ensure collection of appropriate data needed to support approval, as well as possibly more frequent written correspondence from FDA about such matters as the suitability of designs for proposed clinical trials.
About galeterone (TOK-001)
galeterone is a proprietary small molecule, oral drug for the treatment of prostate cancer that disrupts androgen receptor signaling via a novel triple mechanism of action. In preclinical studies, galeterone acts as a highly selective CYP17 lyase inhibitor, as an androgen receptor antagonist, and decreases androgen receptor levels in prostate tumors – the only drug in development that has been shown to exhibit all three of these properties. In galeterone, these three distinct mechanisms of action are combined in one therapeutic compound.
About Tokai Pharmaceuticals
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The company’s lead drug candidate, galeterone (TOK-001), is the first investigational new drug that can decrease overall androgen receptor levels in prostate tumors and in which three distinct mechanisms of action are combined to disrupt androgen receptor signaling in one oncotherapeutic. Privately held Tokai is based in Cambridge, Massachusetts and is backed by Apple Tree Partners and Novartis Venture Fund. For more information on the company and galeterone, please visit www.tokaipharma.com.
Source: Tokai Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.